Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies

1 Nov 2023

Abstract excerpt

Background Approximately 50% of patients who receive anti-CD19 CAR-T cells relapse, and new immunotherapeutic targets are urgently needed. We recently described CD72 as a promising target in B-cell malignancies and developed nanobody-based CAR-T cells (nanoCARs) against it. This cellular therapy design is understudied compared with scFv-based CAR-T cells, but has recently become of significant interest given the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38007238
DOI: 10.1136/jitc-2023-006985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignanciesPMID 38007238Read ↗

Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell MalignanciesSemantic proximity Read ↗

Surface Proteomics Reveals CD72 as a Target for In Vitro –Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1 -Rearranged B-ALLSemantic proximity Read ↗

Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myelomaSemantic proximity Read ↗

Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma TherapySemantic proximity Read ↗

Combinatorial T cell engineering eliminates on-target off-tumor toxicity of CD229 CAR T cells while maintaining anti-tumor activitySemantic proximity Read ↗

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsSemantic proximity Read ↗

Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen induced exhaustionSemantic proximity Read ↗

Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR T cellsSemantic proximity Read ↗

The Application of Nanobody in CAR-T TherapySemantic proximity Read ↗

Computational structural optimization enhances IL13Rα2 – B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escapeSemantic proximity Read ↗

MiniCARbids: Minimalistic human binding domains specifically tailored to CAR T applicationsSemantic proximity Read ↗

Pooled screening for CAR function identifies novel IL13Rα2-targeted CARs for treatment of glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.